Cover Image
市場調查報告書

F. Hoffmann-La Roche Ltd.的產品平台分析

F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253697
出版日期 內容資訊 英文 327 Pages
訂單完成後即時交付
價格
Back to Top
F. Hoffmann-La Roche Ltd.的產品平台分析 F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016
出版日期: 2016年03月16日 內容資訊: 英文 327 Pages
簡介

F. Hoffmann-La Roche Ltd.是總公司在瑞士的醫療保健企業。是研究生技藥品,癌症治療藥,體外診斷(IVD)系統的領先企業,其他也提供癌症、腦部疾病、感染疾病、消耗性疾病、心血管系統疾病、代謝系疾病等的治療藥,POC診斷設備、分析器、血糖值測量儀、研究所資訊、工作流程及資料管理軟體等,多種產品及服務。

本報告提供F. Hoffmann-La Roche Ltd. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

F. Hoffmann-La Roche Ltd. 的基本資料

  • F. Hoffmann-La Roche Ltd. 概要
  • 主要資訊
  • 企業資料

F. Hoffmann-La Roche Ltd. :R&D概要

  • 主要的治療範圍

F. Hoffmann-La Roche Ltd. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 轉出授權產品

F. Hoffmann-La Roche Ltd. :開發中產品概況

  • 後期階段產品開發中產品
  • 在臨床階段的開發中產品
  • 初期階段的開發中產品

F. Hoffmann-La Roche Ltd. :藥物簡介

  • bevacizumab
  • cobimetinib
  • ibandronate sodium
  • omalizumab
  • pertuzumab
  • alectinib
  • alteplase
  • atezolizumab
  • gantenerumab
  • lebrikizumab
  • obinutuzumab
  • ocrelizumab
  • ranibizumab
  • tocilizumab
  • trastuzumab emtansine
  • vemurafenib
  • (danoprevir + ritonavir)
  • basimglurant
  • bitopertin
  • codrituzumab
  • danoprevir
  • emactuzumab
  • imgatuzumab
  • miravirsen
  • pirfenidone
  • RG-1577
  • RG-1662
  • RG-6013
  • RG-7314
  • RG-7697
  • RG-7929
  • RO-5093151
  • setrobuvir
  • TRX-1
  • vanucizumab
  • vismodegib
  • lumretuzumab
  • RG-6016
  • RG-7388
  • RG-7800
  • PRX-002
  • RG-6080
  • RG-7203
  • RG-7304
  • RG-7342
  • RG-7345
  • RG-7356
  • RG-7410
  • RG-7625
  • RG-7641
  • RG-7689
  • RG-7716
  • RG-7775
  • RG-7787
  • RG-7795
  • RG-7802
  • RG-7813
  • RG-7876
  • RG-7880
  • RO-5285119
  • RO-6799477
  • RO-6806127
  • RO-6836191
  • RO-6864018
  • RO-6870868
  • RO-6889678
  • RO-6926496
  • RO-7033877
  • SPC-2968
  • Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases
  • AT-006
  • Benzodiazepinone-36
  • Benzoxazepinone-40
  • CLP-257
  • EZN-3889
  • EZN-3892
  • EZN-3920
  • GAL-F2
  • IMA-930
  • IMA-942
  • IMA-962
  • INO-1800
  • ITMN-10534
  • ITMN-14440
  • ITMN-30162
  • Monoclonal Antibodies to Target DR5 and FAP for Cancer
  • Monoclonal Antibody Conjugates for Solid Tumor
  • Monoclonal Antibody to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections
  • Monoclonal Antibody to Target CD16A for Oncology
  • ranibizumab SR
  • RN-486
  • RO-2959
  • RO-4938581
  • RO-5073012
  • RO-5203280
  • RO-5461111
  • Ro-646198
  • RO-6839328
  • RO-9021
  • Small Molecule to Agonize GPR119 for Type II Diabetes
  • Small Molecules for Myotonic Dystrophy Type 1
  • Small Molecules to Inhibit Janus Kinase 3 for Inflammation
  • Small Molecules to Inhibit PTP1B for Obesity and Type-2 Diabetes
  • Small Molecules to Inhibit Viral RNA Polymerase for Influenza
  • XGFR-2
  • XGFR-4
  • Fluoropyridone-19
  • Monoclonal Antibodies for Cancer
  • Proteins for Cancer
  • RG-7109
  • RO-5454948
  • RO-8994
  • Small Molecule to Activate Glycogen Synthase for Type 2 Diabetes
  • Small Molecule to Inhibit LOXL2 for Fibrosis
  • Small Molecules for Multi-Drug Resistant Gram-Negative Bacterial Infections
  • Small Molecules for Neuropsychiatric Disorders
  • Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis

F. Hoffmann-La Roche Ltd. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

F. Hoffmann-La Roche Ltd. :最近的開發平台資訊

F. Hoffmann-La Roche Ltd. :開發休止的計劃

F. Hoffmann-La Roche Ltd. :開發中止的開發中產品

  • 開發中止的開發中產品簡介

F. Hoffmann-La Roche Ltd. :企業理念

F. Hoffmann-La Roche Ltd. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07982CDB

Summary

Global Markets Direct's, 'F. Hoffmann-La Roche Ltd. - Product Pipeline Review - 2016', provides an overview of the F. Hoffmann-La Roche Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by F. Hoffmann-La Roche Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of F. Hoffmann-La Roche Ltd.
  • The report provides overview of F. Hoffmann-La Roche Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses F. Hoffmann-La Roche Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features F. Hoffmann-La Roche Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate F. Hoffmann-La Roche Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for F. Hoffmann-La Roche Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding F. Hoffmann-La Roche Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • F. Hoffmann-La Roche Ltd. Snapshot
  • F. Hoffmann-La Roche Ltd. Overview
  • Key Information
  • Key Facts
  • F. Hoffmann-La Roche Ltd. - Research and Development Overview
  • Key Therapeutic Areas
  • F. Hoffmann-La Roche Ltd. - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • Pipeline Products - Combination Treatment Modalities
  • Pipeline Products - Partnered Products
  • Pipeline Products - Out-Licensed Products
  • F. Hoffmann-La Roche Ltd. - Pipeline Products Glance
  • F. Hoffmann-La Roche Ltd. - Late Stage Pipeline Products
  • F. Hoffmann-La Roche Ltd. - Clinical Stage Pipeline Products
  • F. Hoffmann-La Roche Ltd. - Early Stage Pipeline Products
  • F. Hoffmann-La Roche Ltd. - Drug Profiles
  • alectinib
  • atezolizumab
  • bevacizumab
  • obinutuzumab
  • omalizumab
  • rituximab
  • alteplase
  • emicizumab
  • gantenerumab
  • idasanutlin
  • lebrikizumab
  • ocrelizumab
  • onartuzumab
  • pertuzumab
  • ranibizumab
  • tocilizumab
  • trastuzumab emtansine
  • vemurafenib
  • olesoxime
  • (danoprevir + ritonavir)
  • basimglurant
  • basmisanil
  • cobimetinib fumarate
  • codrituzumab
  • danoprevir
  • emactuzumab
  • miravirsen
  • RG-7314
  • RG-7716
  • RG-7795
  • RG-7800
  • RO-5093151
  • RO-6864018
  • TRX-1
  • vanucizumab
  • RG-6016
  • cergutuzumab amunaleukin
  • DCDS-0780A
  • lumretuzumab
  • OP-0595
  • PRX-002
  • RG-4929
  • RG-6061
  • RG-6069
  • RG-6078
  • RG-6125
  • RG-7304
  • RG-7386
  • RG-7461
  • RG-7625
  • RG-7775
  • RG-7802
  • RG-7834
  • RG-7876
  • RG-7880
  • RG-7916
  • RG-7944
  • RG-7986
  • RG-7992
  • RO-6799477
  • RO-6806127
  • RO-6836191
  • RO-6870868
  • RO-6874281
  • RO-6874813
  • RO-6889678
  • RO-7020322
  • RO-7033877
  • vismodegib
  • Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases
  • CLP-257
  • GAL-F2
  • Gene Therapy to Activate Telomerase for Aplastic Anemia
  • IMA-930
  • IMA-942
  • IMA-962
  • ITMN-10534
  • ITMN-14440
  • ITMN-30162
  • Monoclonal Antibody Conjugates for Solid Tumor
  • Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections
  • Monoclonal Antibody to Inhibit VEGF-A for Ophthalmology
  • RN-486
  • RO-2959
  • RO-4938581
  • RO-5073012
  • RO-5203280
  • RO-5461111
  • RO-646198
  • RO-6839328
  • RO-6889450
  • RO-9021
  • Small Molecule 2 to Inhibit XIAP for Oncology
  • Small Molecule to Agonize GPR119 for Type II Diabetes
  • Small Molecule to Inhibit XIAP for Oncology
  • Small Molecules for Myotonic Dystrophy Type 1
  • Small Molecules to Inhibit ERG for Prostate Cancer
  • Small Molecules to Inhibit Janus Kinase 3 for Inflammation
  • Small Molecules to Inhibit PTP1B for Obesity and Diabetes
  • Small Molecules to Inhibit Viral RNA Polymerase for Influenza
  • XGFR-2
  • XGFR-4
  • Monoclonal Antibodies for Cancer
  • RG-7109
  • RO-5454948
  • RO-8994
  • Small Molecule to Activate Glycogen Synthase for Type 2 Diabetes
  • Small Molecule to Inhibit LOXL2 for Fibrosis
  • Small Molecule to Inhibit NS5B for Hepatitis C
  • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections
  • Small Molecules for Neuropsychiatric Disorders
  • Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis
  • F. Hoffmann-La Roche Ltd. - Pipeline Analysis
  • F. Hoffmann-La Roche Ltd. - Pipeline Products by Target
  • F. Hoffmann-La Roche Ltd. - Pipeline Products by Route of Administration
  • F. Hoffmann-La Roche Ltd. - Pipeline Products by Molecule Type
  • F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action
  • F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates
  • F. Hoffmann-La Roche Ltd. - Dormant Projects
  • F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products
  • F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • F. Hoffmann-La Roche Ltd. - Company Statement
  • F. Hoffmann-La Roche Ltd. - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • F. Hoffmann-La Roche Ltd., Key Information
  • F. Hoffmann-La Roche Ltd., Key Facts
  • F. Hoffmann-La Roche Ltd. - Pipeline by Indication, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Stage of Development, 2016
  • F. Hoffmann-La Roche Ltd. - Monotherapy Products in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Partnered Products in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • F. Hoffmann-La Roche Ltd. - Out-Licensed Products in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • F. Hoffmann-La Roche Ltd. - Pre-Registration, 2016
  • F. Hoffmann-La Roche Ltd. - Filing rejected/Withdrawn, 2016
  • F. Hoffmann-La Roche Ltd. - Phase III, 2016
  • F. Hoffmann-La Roche Ltd. - Phase II, 2016
  • F. Hoffmann-La Roche Ltd. - Phase I, 2016
  • F. Hoffmann-La Roche Ltd. - Preclinical, 2016
  • F. Hoffmann-La Roche Ltd. - Discovery, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Target, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Route of Administration, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Molecule Type, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline Products by Mechanism of Action, 2016
  • F. Hoffmann-La Roche Ltd. - Recent Pipeline Updates, 2016
  • F. Hoffmann-La Roche Ltd. - Dormant Developmental Projects,2016
  • F. Hoffmann-La Roche Ltd. - Discontinued Pipeline Products, 2016
  • F. Hoffmann-La Roche Ltd., Subsidiaries

List of Figures

  • F. Hoffmann-La Roche Ltd. - Pipeline by Top 10 Indication, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Stage of Development, 2016
  • F. Hoffmann-La Roche Ltd. - Monotherapy Products in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Partnered Products in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Out-Licensed Products in Pipeline, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Top 10 Target, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Route of Administration, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline by Top 10 Molecule Type, 2016
  • F. Hoffmann-La Roche Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top